PubMed چکیده/رکورد

Clinical efficacy and safety of indomethacin-gyneFix IUD combined with a levonorgestrel-releasing intrauterine system in patients with adenomyosis and different uterine cavity depths.

استودیوی صوتی مقاله

پخش حرفه‌ای فارسی و انگلیسی

در حال بررسی نسخه‌های صوتی ذخیره‌شده…

صوت تولیدشده با هوش مصنوعی است. برای کاربرد علمی یا درمانی، متن و منبع اصلی را بررسی کنید.
خواندن هوشمند فارسی و انگلیسی در حال آماده‌سازی صداهای مرورگر…
تنظیم صدای طبیعی و سرعت

صداهایی که در نامشان «Natural»، «Neural» یا «Online» دیده می‌شود معمولاً طبیعی‌ترند. انتخاب صدا به صداهای نصب‌شده در ویندوز و مرورگر شما بستگی دارد.

چکیده اصلی

BACKGROUND: Adenomyosis is commonly associated with dysmenorrhea and heavy menstrual bleeding. Although the levonorgestrel-releasing intrauterine system (Mirena, LNG-IUS) is recommended as a first-line conservative treatment, device displacement or expulsion remains a major limitation, especially in patients with enlarged uteri or deep uterine cavities. OBJECTIVES: To evaluate the clinical efficacy and safety of the Indomethacin-GyneFix IUD (GyneFix IUD) combined with LNG-IUS in patients with adenomyosis and to assess whether uterine cavity depth influences device stability. METHODS: In this single-center prospective randomized controlled trial, 270 patients with adenomyosis were randomly assigned in a 1:1:1 ratio to the GyneFix IUD + LNG-IUS group, the ring IUD + LNG-IUS group, or the LNG-IUS-alone group (90 patients each). The primary endpoint was the rate of device displacement/expulsion at 6 months. Secondary endpoints included changes in visual analogue scale (VAS) scores, pictorial blood loss assessment chart (PBAC) scores, uterine volume, hemoglobin (Hb), serum CA125, adverse events and patient acceptance. Subgroup analysis was performed according to uterine cavity depth (≤ 9cm vs. >9 cm). RESULTS: At 6 months, the displacement/expulsion rate was significantly lower in the GyneFix IUD + LNG-IUS group (2.22%) than in the ring IUD + LNG-IUS group (10.00%) and the LNG-IUS-alone group (18.89%) (χ2=13.468, P<0.001). All three groups showed significant improvement in dysmenorrhea, menstrual blood loss, Hb and CA125 compared with baseline, without significant between-group differences (all P>0.05). Adverse event rates were comparable among groups (all P>0.05). Patient willingness to choose the same treatment again (95.12%) and willingness to recommend it (90.24%) were significantly higher in the GyneFix IUD + LNG-IUS group. In patients with uterine cavity depth >9 cm, the stability advantage of this strategy was more pronounced. CONCLUSION: GyneFix IUD combined with LNG-IUS significantly reduces device displacement/expulsion in adenomyosis, particularly in patients with deeper uterine cavities, while maintaining comparable symptom relief and safety. It may represent a more stable and acceptable long-term conservative treatment option.

متن کامل اصلی

متن در JumpToDate ذخیره نشده است.

برای بررسی دسترسی کتابخانه‌ای یا خرید، رکورد اصلی را باز کنید.

رفتن به منبع اصلی

کلیدواژه‌ها

AdenomyosisGenetecIntrauterine device displacementLevonorgestrel intrauterine systemRandomized controlled trialUterine depth
در همین زیرشاخه

مقاله‌های مرتبط

PubMed2026

ATI-2341 TFA promotes acquisition of epithelial-like immunophenotype in bone marrow mesenchymal stem cells and alleviates intrauterine adhesion in a rat model.

BACKGROUND: Intrauterine adhesion (IUA) is a common complication of endometrial injury. Bone marrow mesenchymal stem cells (BMSCs) have been implicated in endometrial repair, but strategies to enhance their therapeutic efficacy remain to be optimized. The C-X-C chemokine receptor type 4 (CXCR4)/C-X-C motif chemokine ligand 12 (CXCL12) axis plays a pivotal role in BMSC homing. OBJECTIVE: This study aimed to test the hypothesis that ATI-…

PubMed2026

Duo Nang Decoction enhances endometrial receptivity in PCOS rats by upregulating caveolin-1 expression.

BACKGROUND: Duo Nang Decoction (DND) is widely used for treating polycystic ovary syndrome (PCOS)-related infertility. However, the molecular mechanisms underlying its action remain unclear. In a previous study, downregulation of caveolin-1 (Cav-1) was shown to impair endometrial angiogenesis, a key determinant of endometrial receptivity. OBJECTIVES: This research study aimed to elucidate the influence and potential molecular mechanism…

PubMed2026

MicroRNA-135 alleviates cisplatin resistance in cervical cancer by inhibiting CD44v6.

BACKGROUND: Cervical cancer (CC) remains a leading cause of cancer-related mortality worldwide and cisplatin resistance poses a major challenge to effective treatment. MicroRNA-135 (miR-135) has been implicated in tumor progression and drug resistance, but its role in cisplatin-resistant CC remains unclear. OBJECTIVES: To investigate whether miR-135 affects cisplatin resistance in CC cells by targeting CD44v6. METHODS: Bioinformatic an…

PubMed2026

Acceptability and preference of self-collected vaginal samples for human papillomavirus DNA testing compared with physician-collected Pap smear.

BACKGROUND: Self-collected vaginal sampling for human papillomavirus (HPV) DNA testing provides a promising alternative to physician-collected Pap smears, especially in low-resource settings. However, data on its acceptability and preferences among Filipino women remain limited. This study aimed to assess women's perceptions, experiences, willingness and preferences regarding self-collected vaginal sampling for HPV DNA testing compared…